CD4 and herpes zoster: gE-M also showed stable advantages in all of the indicators tested for CMI that play decisive roles in the efficacy of zoster vaccines, including gE-specific IFN-γ/IL-2-producing splenocyte numbers analyzed by ELISPOT (Figure 3) and the proportion of gE-specific IFN-γ-producing CD4+/CD8+ T cells among splenocytes analyzed by flow cytometry analysis (Figure 4) [4,5,6,7,8,9].